Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 17, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.
Journal: JCO precision oncology
Published: August 29, 2024
RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?
Journal: Journal of the National Cancer Institute
Published: June 24, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 19, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 14, 2024
Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis.
Journal: Journal of the National Cancer Institute
Published: December 21, 2023
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 21, 2023
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Journal: Bladder cancer (Amsterdam, Netherlands)
Published: July 27, 2023
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 04, 2022
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Journal: European urology
Published: October 27, 2022
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 16, 2022
Last Updated: 09/26/2026